KIELTYKA GLADKOWSKI KG LEGAL to deliver a lecture at LSOS Summit 2024: Cultural and legal aspects of entering the Middle East and Africa (MEA) market of medicines, medical devices and dietary supplements
Publication date: November 04, 2024
We are proud to share the news that KIELTYKA GLADKOWSKI KG LEGAL will take an active part in Life Science Open Space Summit 2024.
This is a flagship business and conference event organized annually for over a decade by the largest organization in the health and environmental protection market in Poland, LIFE SCIENCE CLUSTER POLAND, with the status of a KEY NATIONAL CLUSTER, founded by both leaders among Polish biotechnology companies (e.g. SELVITA) and by educational institutions of higher education (Jagiellonian University).
KIELTYKA GLADKOWSKI KG LEGAL is a proud member of the Life Science Cluster.
On behalf of KIELTYKA GLADKOWSKI KG LEGAL, the lecture will be delivered by Zaid Jaber, Pharmacy BSc and IP specialist within pharma patents. Zaid cooperates with KIELTYKA GLADKOWSKI KG LEGAL in connection with his activities at the Jagiellonian University within New Technologies and IP law.
KIELTYKA GLADKOWSKI KG LEGAL highly values its international environment of cooperation and has aspirations to become the platform for specialists within international law and life sciences sector.
During his presentation, Zaid will share very practical information on how to enter MEA pharma markets, with regard to certification, regulatory matters and primarily cultural and religious differences and challenges.
Zaid will focus on the so-called Halal certification and the rules and practical recommendations of how to obtain this certificate.
Halal certification applies to the food, cosmetics, and pharmaceuticals sectors, confirming that a product is manufactured in full compliance with Islamic law, does not contain any forbidden components, and has not come into contact with any substances considered impure. This certification is granted to ensure Islamic consumers that their religious precepts have been respected and that the product maintains a high level of hygiene and safety.
Please see more on the problem of entering MEA markets with pharma products on our blog:
